Float Short %

23.79

Margin Of Safety %

Put/Call OI Ratio

0.08

EPS Next Q Diff

-0.01

EPS Last/This Y

-0.06

EPS This/Next Y

Price

0.7

Target Price

6.5

Analyst Recom

Performance Q

4.52

Relative Volume

0.84

Beta

4.2

Ticker: OCGN

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	OCGN	0.6793	0.06	0.03	37191
2025-04-15	OCGN	0.6955	0.06	0.01	37313
2025-04-16	OCGN	0.6536	0.06	0.22	37524
2025-04-17	OCGN	0.6823	0.06	0.00	37557
2025-04-18	OCGN	0.6794	0.06	0.01	37557
2025-04-21	OCGN	0.6786	0.08	0.00	24083
2025-04-22	OCGN	0.6877	0.08	0.01	24606
2025-04-23	OCGN	0.7195	0.08	0.00	25035
2025-04-24	OCGN	0.7359	0.08	0.18	25404
2025-04-25	OCGN	0.7192	0.076827397487458	0.032345013477089	25972
2025-04-28	OCGN	0.7077	0.076472035427259	0.0083682008368201	26253
2025-04-29	OCGN	0.7261	0.08	0.01	26315
2025-04-30	OCGN	0.747	0.08	0.01	26350
2025-05-01	OCGN	0.7381	0.08	0.00	26669
2025-05-02	OCGN	0.7696	0.07	0.00	26965
2025-05-05	OCGN	0.7675	0.07	0.01	27378
2025-05-06	OCGN	0.7159	0.07	0.05	27762
2025-05-07	OCGN	0.6615	0.07	0.14	27787
2025-05-08	OCGN	0.693	0.07	0.17	27872
2025-05-09	OCGN	0.6696	0.08	0.03	28647
2025-05-12	OCGN	0.6943	0.08	0.14	28858
2025-05-13	OCGN	0.7025	0.08	0.00	29080
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	OCGN	0.67	-20.0	-	-0.26
2025-04-15	OCGN	0.70	-20.0	-	-0.26
2025-04-16	OCGN	0.65	-20.0	-	-0.26
2025-04-17	OCGN	0.68	-20.0	-	-0.26
2025-04-18	OCGN	0.68	-20.0	-	-0.26
2025-04-21	OCGN	0.68	-20.0	-	-0.26
2025-04-22	OCGN	0.69	-20.0	-	-0.26
2025-04-23	OCGN	0.72	-20.0	-	-0.26
2025-04-24	OCGN	0.74	-20.0	-	-0.26
2025-04-25	OCGN	0.72	-20.0	-	-0.26
2025-04-28	OCGN	0.71	-20.0	-	-0.26
2025-04-29	OCGN	0.73	-20.0	-	-0.26
2025-04-30	OCGN	0.75	-20.0	-	-0.26
2025-05-01	OCGN	0.74	-20.0	-	-0.26
2025-05-02	OCGN	0.76	-20.0	-	-0.26
2025-05-05	OCGN	0.76	-20.0	-	-0.26
2025-05-06	OCGN	0.71	-20.0	-	-0.26
2025-05-07	OCGN	0.66	-20.0	-	-0.26
2025-05-08	OCGN	0.69	-20.0	-	-0.26
2025-05-09	OCGN	0.67	-20.0	-	-0.26
2025-05-12	OCGN	0.70	-20.0	-	-0.26
2025-05-13	OCGN	0.70	-20.0	-	-0.26
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	OCGN	0.67	-10.03	22.94
2025-04-15	OCGN	0.67	-10.03	22.94
2025-04-16	OCGN	0.67	-10.03	22.94
2025-04-17	OCGN	0.67	-10.03	22.94
2025-04-18	OCGN	0.67	-10.03	22.94
2025-04-21	OCGN	0.67	-10.30	22.94
2025-04-22	OCGN	0.67	-10.30	22.94
2025-04-23	OCGN	0.67	-10.30	22.94
2025-04-24	OCGN	0.67	-10.30	22.94
2025-04-25	OCGN	0.67	-10.30	22.94
2025-04-28	OCGN	0.67	-10.33	23.95
2025-04-29	OCGN	0.67	-10.33	23.95
2025-04-30	OCGN	0.67	-10.33	23.95
2025-05-01	OCGN	0.67	-10.33	23.95
2025-05-02	OCGN	0.67	-10.33	23.95
2025-05-05	OCGN	0.67	-10.28	23.95
2025-05-06	OCGN	0.67	-10.28	23.95
2025-05-07	OCGN	0.67	-10.28	23.95
2025-05-08	OCGN	0.67	-10.28	23.95
2025-05-09	OCGN	0.67	-10.28	23.95
2025-05-12	OCGN	0.67	-12.59	23.79
2025-05-13	OCGN	0.67	-12.59	23.79
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.05

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

0.67

Institutional Transactions

-12.59

Beta

4.2

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

96.3

Max Drawdown 5-Year %

-97.7

Target Price

6.5

P/E

Forward P/E

PEG

P/S

45.39

P/B

12.89

P/Free Cash Flow

EPS

-0.19

Average EPS Est. Cur. Y

-0.26

EPS Next Y. (Est.)

-0.26

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1160.86

Relative Volume

0.84

Return on Equity vs Sector %

-384.9

Return on Equity vs Industry %

-367.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

Ocugen, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 95

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

stock quote shares OCGN – Ocugen, Inc. Stock Price stock today

news today OCGN – Ocugen, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch OCGN – Ocugen, Inc. yahoo finance google finance

stock history OCGN – Ocugen, Inc. invest stock market

stock prices OCGN premarket after hours

ticker OCGN fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: OCGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y